ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

4:00PM-5:30PM: Abstract Number: 1683

Moving the ACR’s Reproductive Health Guidelines into Practice: Assessment of a Novel Reproductive Rheumatology ECHO

Abstracts: Reproductive Issues in Rheumatic Disorders

4:00PM-5:30PM: Abstract Number: 1696

Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Omics

4:00PM-5:30PM: Abstract Number: 1702

Outcomes in Systemic Sclerosis Patients Treated with Rituximab and Mycophenolate Mofetil Combination Therapy Compared to Autologous Hematological Stem Cell Transplantation

Abstracts: Systemic Sclerosis & Related Disorders II: Clinical Research

4:00PM-5:30PM: Abstract Number: 1682

Prospective Evaluation of Anti-SSA/Ro Pregnancies Supports the Utility of High Titer Antibodies and Fetal Home Monitoring for the Detection of Fetal Atrioventricular Block

Abstracts: Reproductive Issues in Rheumatic Disorders

4:00PM-5:30PM: Abstract Number: 1674

Severe Infections in Patients with VEXAS Syndrome: A Study from the French VEXAS Group

Abstracts: Infection-related Rheumatic Disease

4:00PM-5:30PM: Abstract Number: 1687

Sex of the Patient Affects Response to Advanced Therapies in Psoriatic Arthritis: Meta-analysis of Data from Randomized Controlled Trials

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA

4:00PM-5:30PM: Abstract Number: 1695

Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Omics

4:00PM-5:30PM: Abstract Number: 1685

SLE Disease Activity Is a More Important Risk Factor Than Immunosuppression for Acquiring Human Papillomavirus (HPV) Infection in Systemic Lupus Erythematosus Patients

Abstracts: Reproductive Issues in Rheumatic Disorders

4:00PM-5:30PM: Abstract Number: 1661

Spatial Transcriptional Alterations in the Cellular Landscape of Pediatric Scleroderma Skin

Abstracts: Pediatric Rheumatology – Basic Science

4:00PM-5:30PM: Abstract Number: 1660

Still’s Disease Patients with High Interferon-stimulated Gene Expression Have Enrichment of Rare, de Novo and Recessive Protein Altering Variants in Innate Immune Pathways

Abstracts: Pediatric Rheumatology – Basic Science

4:00PM-5:30PM: Abstract Number: 1675

Survival in Patients with Rheumatoid Arthritis and Early Breast Cancer Treated with Tumor Necrosis Factor Inhibitors

Abstracts: RA – Treatments II: RA Treatment Safety

4:00PM-5:30PM: Abstract Number: 1681

Tacrolimus Use in SLE Pregnancy and Its Effect on Pregnancy Outcomes: Retrospective Study in Two Japanese Tertiary Referral Centers

Abstracts: Reproductive Issues in Rheumatic Disorders

4:00PM-5:30PM: Abstract Number: 1684

The Impact of Pregnancy Timing on Outcomes in SLE

Abstracts: Reproductive Issues in Rheumatic Disorders

4:00PM-5:30PM: Abstract Number: 1658

Title: Inflammatory Arthritis Across the Age-Spectrum: Single-Cell Profiling of the Inflamed Synovium in Children with Juvenile Idiopathic Arthritis

Abstracts: Pediatric Rheumatology – Basic Science

4:00PM-5:30PM: Abstract Number: 1666

TNF-mediated Pulmonary Hypertension Is Marked by Aberrant Bone Morphogenic Protein (BMP) and Integrin/Basement Membrane Ligand-Receptor Signaling

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].